Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 2

Healio

WASHINGTON — In the ADAPT-TAVR trial of patients who had transcatheter aortic valve replacement and no indication for long-term anticoagulation, edoxaban did not improve